Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217. Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA.
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit www.phanesthera.com.
For business development or media inquiries, please contact bd@phanestx.com or media@phanestx.com respectively.
Company Details
- Employees
- 27
- Founded
- -
- Address
- 11535 Sorrento Valley Rd,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.phanesthera.com/
- HQ
- San Diego, California
Phanes Therapeutics, Inc. Questions
Phanes Therapeutics, Inc.'s website is https://www.phanesthera.com/
Phanes Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/phanesthera
Phanes Therapeutics, Inc. has
27 employees.
View email and phone details for 27
employees at Phanes Therapeutics, Inc..
Phanes Therapeutics, Inc.'s industry is
Biotechnology Research
Phanes Therapeutics, Inc.'s top competitors are
Crinetics Pharmaceuticals,
Ionis Pharmaceuticals, Inc.,
Kura Oncology, Inc.,
Gt Biopharma, Inc.,
Janux Therapeutics,
Astrazeneca,
Arrowhead Pharmaceuticals,
Bps Bioscience Inc.,
Neurocrine Biosciences,
Xencor.
Phanes Therapeutics, Inc.'s categories are Biotechnology Research
Phanes Therapeutics, Inc.'s founding year is 2016
